Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roxy Senior

Showing results (291-300 of 320) with videos related to

Pageof 32
Sort By:
Open Heart|September 4, 2023
Time to TAVI: streamlining the pathway to treatmentLynsey Jane Hewitson, Suzane Cadiz, Sameeha Al-Sayed, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|August 22, 2013
Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIALawrence M Phillips, Rory Hachamovitch, Daniel S Berman, et al.
Circulation. Cardiovascular Quality and Outcomes|September 20, 2024
International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA TrialNobuhiro Ikemura, John A Spertus, Dan Nguyen, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
Lancet (London, England)|August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialJohn G F Cleland, John R Teerlink, Roxy Senior, et al.
JAMA Cardiology|October 25, 2023
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 TrialDivaka Perera, Matthew Ryan, Holly P Morgan, et al.
Circulation|June 1, 2021
Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA StudyHarmony R Reynolds, Michael H Picard, John A Spertus, et al.
Circulation. Cardiovascular Interventions|April 12, 2022
Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA TrialSripal Bangalore, John A Spertus, Susanna R Stevens, et al.
Echo Research and Practice|February 21, 2025
Multi-societal expert consensus statement on the safe administration of ultrasound contrast agentsJordan B Strom, Andrew Appis, Richard G Barr, et al.
European Heart Journal|August 30, 2024
2024 ESC Guidelines for the management of chronic coronary syndromesChristiaan Vrints, Felicita Andreotti, Konstantinos C Koskinas, et al.
Pageof 32

Showing results (291-300 of 320) with videos related to

Sort By:
Pageof 32
Open Heart|September 4, 2023
Time to TAVI: streamlining the pathway to treatmentLynsey Jane Hewitson, Suzane Cadiz, Sameeha Al-Sayed, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|August 22, 2013
Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIALawrence M Phillips, Rory Hachamovitch, Daniel S Berman, et al.
Circulation. Cardiovascular Quality and Outcomes|September 20, 2024
International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA TrialNobuhiro Ikemura, John A Spertus, Dan Nguyen, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
Lancet (London, England)|August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialJohn G F Cleland, John R Teerlink, Roxy Senior, et al.
JAMA Cardiology|October 25, 2023
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 TrialDivaka Perera, Matthew Ryan, Holly P Morgan, et al.
Circulation|June 1, 2021
Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA StudyHarmony R Reynolds, Michael H Picard, John A Spertus, et al.
Circulation. Cardiovascular Interventions|April 12, 2022
Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA TrialSripal Bangalore, John A Spertus, Susanna R Stevens, et al.
Echo Research and Practice|February 21, 2025
Multi-societal expert consensus statement on the safe administration of ultrasound contrast agentsJordan B Strom, Andrew Appis, Richard G Barr, et al.
European Heart Journal|August 30, 2024
2024 ESC Guidelines for the management of chronic coronary syndromesChristiaan Vrints, Felicita Andreotti, Konstantinos C Koskinas, et al.
Pageof 32